Colorectal cancer (CRC) is one of the most common cancers with high mortality, and a poor prognosis has been associated with the biomarker, CD24, which can be expressed on cancer stem cells. This research aimed to evaluate the expression of CD24 in CRC and its correlation with clinical-pathological characteristics by immunohistochemistry on paraffin-embedded specimens from patients treated at three hospitals in Kirkuk. Expression of CD24 was demonstrated in 58% of the cases with strong, moderate and weak staining seen in 41.3%, 48.2% and 10.3% of the positive tumours respectively; most demonstrated diffuse expression (68.9%). Expression was more commonly found in males and 62.1% in colon site tumors male and 62.1% respectively predominated than in the female gender, with a peak prevalence at adenocarcinomas (96.6%) at age groups of between 41–50 and +61–70 years. It is interesting to note that both relapse and treatment-refractory samples tested positive for CD24, indicating a potential association with recurrence and resistance. These data suggest that CD24 is commonly expressed in CRC, and correlates with tumour aggressiveness with potential prognostic as well as therapeutic implication, warranting larger validation studies.